Tagged with ART

adherence Adherence solutions company Atlantis Healthcare founded its Spanish affiliate in 2010. Ana Maria Arboleda, managing director, discusses adherence issues in Spain and efforts to ensure that patients remain committed to their medication treatment.   What was the inspiration for creating Atlantis Healthcare in Spain? 15 years ago, we had a…

partnerships “We are glad to host, together with ETIF, an event bringing forward pharma technologies to Argentinian patients. We hope this collaboration with ETIF will be the first of many” – Ines Nandin, Publisher, PharmaBoardroom The eighth biennial Pharmaceutical Industry Technology Event (ETIF) took recently took place in Buenos Aires, running from…

biotech The founder of this spin-off of the Autonomous University of the State of Morelos focusing on biologicals for human and veterinary use offers an overview of how the company came into life, the lack of culture at Mexican universities of filing patents for academic research and the potential of the…

biotech Bioceres manages investments in agricultural biotechnology and related sciences. The company’s CEO, Federico Trucco, discusses the potential of Argentina’s biotech scene to become a world-class drug developer in biopharma as well as Bioceres’ own investments in the sector.   How did you become involved with Bioceres? I have known the…

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

clinical trials Klinsel’s CEO discusses the company’s ambitions of growth in a very competitive CRO market and stresses that local experience is truly a distinguishing factor and this is why they are already partnering and performing trials for one of the country’s largest local manufacturers.     Klinsel was appointed last year…

medical devices The CEO and one of the founders of Lexel explains how the company adapts its medical devices to the specifications required by their international customers.   Why did Lexel enter into the medical device market and most important, where did you see the opportunities when creating this company? From the…

Sandoz The general manager of Sandoz South Latam weighs up the factors that have allowed his company to be the leader in biosimilars and differentiated generics.     Could you please give us a broad overview of the generics market in Argentina over the last decade? The dynamics of the generic…

hospital The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to become the market leader in Asia by offering a comprehensive range of services for cardiovascular medicine with a wide range…

Cell2B David Malta and Daniela Couto, Co-founders of Cell2B, discuss the company’s origins and plans to achieve market authorization, and what makes the fledgling company the partner of choice.   What do you see as Portugal’s capacity for the local life sciences industry to grow? DM: Portugal is one of the best-positioned…